2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Workforce, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, GVD, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Research, Fundamental Science, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6134 Using quality improvement processes to better understand barriers to hydroxyurea dosing at a large pediatric institution

Cynthia Norris, MD, Elizabeth Pumiglia, MSN, CRNP2, Alicia Brandemarte, MS3, Rebecca Brugger, MSN, RN, CPHON4, Jennifer Randall, MSN, RN, CRNP, PPCNP-BC5, Karmilla Cowlay, BSN, RN6, Alexandra Kaspin, MSN, RN7, Kyisha Knox, BSN, RN8, Shyla Pelletier, RN9, Christina Procacci, BA, MS10, Shannon Kelleher, MPH, LSSGB11
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Introduction: Despite the American Society of Hematology guidelines recommendation to offer hydroxyurea (HU) to patients with sickle cell disease (SCD) types-SS or S beta 0 thalassemia at 9 months of age, many challenges remain for prescribing and dosing HU in children.  For a variety of issues, both at the provider -, health system - and patient-level, a significant percentage of children are not receiving HU and those that are receiving it may not be at maximum tolerated dose (MTD).  To better address these issues, our hospital supported a quality improvement (QI) project to better understand HU prescribing and dosing.

 

Methods: The HU QI group was initiated to gather and track metrics related to HU prescribing.  The group met regularly for three years to identify barriers and create PDSA (Plan, Do, Study and Act) cycles to address them. One intervention, provider education, outlined clear goals of therapy and provided information on various formulations, dosing guidelines and toxicity monitoring schedules. Providers were encouraged to use one of 3 area pharmacies with home delivery, were reminded about dose escalation/need for refills the week prior to an upcoming clinic visit and prompted to order a 3-month supply for those receiving HU at MTD. To address patient and caregiver barriers, during office visits, Child Life support was offered to assist with pill swallowing, photos were shown comparing the different capsule and tablet sizes to improve understanding of the options and families were provided with pill boxes or cutters if indicated. Patient/caregiver education focused on reviewing trends in hemoglobin (Hb), Hb F%, mean corpuscular volume (MCV), platelet count, reticulocyte count and absolute neutrophil count (ANC) values over time to show the relationship of current values to individual personal best values. Updated patient education regarding HU was shared with patients/families via several formats. To address system-level barriers, hospital leadership advocated with state Medicaid payors to expand the HU formulations offered and simplify/eliminate the need for prior authorization. A provider EMR smart form was created to capture data regarding HU use at each visit.  This allowed schedulers and nursing to ensure timely lab follow up and avoid medication lapses. A population health tool (Healthy Planet; HP) database was created in Epic to monitor lab values and items from the smart form in real-time with the ability to enter the patient chart directly from HP as opposed to cumbersome spread sheets which we had used previously.
 

Results: Our institution follows 476 patients with SCD-SS or SCD-S beta 0 thalassemia between 9 months and 22 years of age. One hundred percent of patients were offered HU. Twenty four percent (114/476) of patients were not prescribed HU.  For these patients, 48 (42%) were on chronic transfusion therapy, 17 (15%) patients/families declined, 16 (14%) had labs that met the goals of therapy without HU, 5 (4%) had toxicity that required HU discontinuation, 3 (3%) were post stem cell therapy and 25 (22%) had other reasons. Seventy-six percent (362/476) of patients were prescribed HU; 160 (44%) were dose-escalating and 202 (56%) were on a stable dose. Of those on a stable dose, 97 (48%) patients met the goals of therapy, 58 (29%) were at MTD due to meeting maximum recommended dose, 23 (11%) were at MTD because of clinical or laboratory toxicity, 4 (2%) were by patient/family preference, and 20 (10%) were holding at current dose for unclear reasons.

 

Conclusion: One hundred percent of our eligible patients are offered HU and 76% receive prescriptions for HU. Of those prescribed HU, 44% of patients were still dose-escalating and not yet at MTD.  The use of HP may enable more timely HU dose escalation, fewer lapses in patient prescriptions and less time spent by providers and staff on HU management. Future goals will focus on more rapid dose escalation guidelines and patient focused strategies to improve adherence and manage of clinical side effects.

Cynthia Norris, MD: No relevant conflicts of interest to declare.